Egyptian Drug Authority

 
Services > Pharmacoeconomic Unit > Technology Appraisals

Technology Appraisals

  Deferasirox TA report
  Denosumab TA report
  Dasatinib TA report
  Imipenem-cilastatin TA report
  Insulin Detemir - Type I DM - TA report
  Insulin Detemir - Type II DM - TA report
  Lapatinib and Trastuzumab - TA report
  Sorafinib TA report
  Aprepitant TA report
  Anagrelide TA report
  Bortezomib TA report
  Cerezyme TA report
  Darbepoetin TA report
  Everolimus TA report
  Fidaxomicin TA report
  Insulin TA report
  Lidocaine-Prilocaine TA report
  Lenalidomide TA report
  Lapatinib TA report
  Lipiodol TA report
  Sapropterin TA report
  Taxanes TA report
  Zoledronic TA report
  Cabergoline TA report
  Nilotinib TA report
  Teriparatide TA report
  Denosumab TA report
  Omeprazole TA report
  Palonosetron TA report
  Zoledronic acid TA report
 
Back